Particularly ICIs targeting programmed cell death protein 1 (PD-1), its ligand PD-L1 or cytotoxic T lymphocyte-associated protein 4 (CTLA-4), have achieved extraordinary success in treating cancers such as non-small cell lung cancer (NSCLC) [8]. Here, CTLA4 is linked to non-small cell lung carcinoma.